Caredx Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
49.5%projected annual EPS growth
Analyst Coverage
6analysts covering
FY Revenue (est.)
$495.2Mnext fiscal year
FY EPS (est.)
$1.21next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Testing Services Revenue Quarterly91MTarget: 306000000 to 326000000
Testing Services Volume Quarterly54.9KTarget: Double-digit annual volume growth
Average Revenue Per Test Quarterly1.7KTarget: Stabilization around 1400 to 1450 excluding prior period collections
Watch Items
- CMS Local Coverage Determination (LCD) Policy ResolutionTrigger: Final LCD release or policy implementationAction: Assess impact on Medicare reimbursement rates and adjust FY2026/2027 revenue projections accordingly.
- Naveris Acquisition Integration and GrowthTrigger: Closing of transaction in Q3 2026Action: Monitor TTMV DNA platform adoption, active ordering physician count, and progress toward the 30% to 40% annual growth target.
- Lab Products Divestiture to Eurobio ScientificTrigger: Closing of transaction in Q3 2026Action: Verify receipt of $170 million cash consideration and track transition services execution.
Research as of 19 Jun 2026